Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs
- PMID: 9875876
- DOI: 10.1001/jama.280.24.2088
Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs
Abstract
Context: Chronic hepatitis C (CHC) infection affects nearly 4 million people in the United States. Treatment with interferon alfa-2b has been limited by its cost and low likelihood of long-term response.
Objective: To examine the cost-effectiveness of alternative pretreatment management strategies for patients with CHC.
Design: Decision and cost-effectiveness analysis using a Markov model to examine prevalence of genotypes, viral load, and histological characteristics in relation to the sustained response rate with treatment. Data were based on a previously published decision model and a MEDLINE literature search for hepatitis C, biopsy, and liver from 1966 to 1996.
Patients: A hypothetical population of patients with CHC infection and elevated serum alanine aminotransferase level.
Interventions: Combinations of liver biopsy, genotyping, and quantitative viral load determination prior to a single 6-month course of interferon alfa-2b; empirical interferon treatment; and conservative management.
Main outcome measures: Proportion of sustained responders, lifetime costs, life expectancy, and quality-adjusted life expectancy.
Results: Strategies involving hepatitis C virus (HCV) RNA testing had marginal cost-effectiveness ratios up to $4400 per discounted quality-adjusted life-year gained but would miss up to 36% of sustained responders. Empirical interferon treatment had a marginal cost-effectiveness ratio of $12400 per discounted quality-adjusted life-year gained and reached all potential sustained responders. Strategies involving liver biopsy were more expensive and would miss 6% of sustained responders and yield slightly lower life expectancies.
Conclusions: Routine liver biopsy before treatment with interferon increases the cost of managing patients with CHC without improving health outcomes. Using quantitative HCV RNA testing to guide therapy misses some potential sustained responders. Empirical interferon treatment has a marginal cost-effectiveness ratio within the bounds of other commonly accepted therapies and misses none of the sustained responders.
Comment in
-
Cost-effectiveness of interferon treatment for hepatitis C.JAMA. 1999 Jun 9;281(22):2083; author reply 2084. JAMA. 1999. PMID: 10367809 No abstract available.
-
Cost-effectiveness of interferon treatment for hepatitis C.JAMA. 1999 Jun 9;281(22):2083-4. JAMA. 1999. PMID: 10367810 No abstract available.
Similar articles
-
Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.JAMA. 2003 Jul 9;290(2):228-37. doi: 10.1001/jama.290.2.228. JAMA. 2003. PMID: 12851278
-
Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.Am J Gastroenterol. 2004 Aug;99(8):1490-6. doi: 10.1111/j.1572-0241.2004.30286.x. Am J Gastroenterol. 2004. PMID: 15307866
-
Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C.Ann Intern Med. 1997 Nov 15;127(10):855-65. doi: 10.7326/0003-4819-127-10-199711150-00001. Ann Intern Med. 1997. PMID: 9382363
-
A pragmatic and cost-effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C.Eur J Gastroenterol Hepatol. 2001 May;13(5):483-8. doi: 10.1097/00042737-200105000-00004. Eur J Gastroenterol Hepatol. 2001. PMID: 11396525 Review.
-
Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review.Health Technol Assess. 2000;4(33):1-67. Health Technol Assess. 2000. PMID: 11134916 Review.
Cited by
-
Estimating future hepatitis C morbidity, mortality, and costs in the United States.Am J Public Health. 2000 Oct;90(10):1562-9. doi: 10.2105/ajph.90.10.1562. Am J Public Health. 2000. PMID: 11029989 Free PMC article.
-
Management of solitary 1 cm to 2 cm liver nodules in patients with compensated cirrhosis: a decision analysis.Can J Gastroenterol. 2007 Aug;21(8):491-500. doi: 10.1155/2007/182383. Can J Gastroenterol. 2007. PMID: 17703248 Free PMC article. Review.
-
Identifying infectious diseases in prisons: surveillance, protection, and intervention.West J Med. 1999 Mar;170(3):177. West J Med. 1999. PMID: 10214108 Free PMC article. No abstract available.
-
Diffusion-weighted imaging of the liver: Current applications.World J Radiol. 2016 Nov 28;8(11):857-867. doi: 10.4329/wjr.v8.i11.857. World J Radiol. 2016. PMID: 27928467 Free PMC article. Review.
-
Diffusion weighted MRI in chronic viral hepatitis: correlation between ADC values and histopathological scores.Insights Imaging. 2013 Jun;4(3):339-45. doi: 10.1007/s13244-013-0252-x. Epub 2013 May 11. Insights Imaging. 2013. PMID: 23666523 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical